E-filed

Attorney Docket No. 38447-201N01 US

Date of Deposit: March 30, 2009

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Christof Westenfelder Confirmation No.: 6531

SERIAL NUMBER: 10/551,317 EXAMINER: WEHBE, Anne Marie

Sabrina

FILING DATE: August 21, 2006 ART UNIT: 1633

FOR: Stem-cell, precursor cell, or target cell-based treatment of multiorgan failure

and renal dysfunction

## MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609.04(a)(II), copies of the cited U.S. publications are not required.

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action. Accordingly, no fee or certification is due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO/SB/08a to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by

Attorney Docket No. 38447-201N01 US

Christof Westenfelder U.S. Appln. No. 10/551,317

35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **38447-201N01US**.

Respectfully submitted,

/Sean M. Coughlin/

Ivor R. Elrifi, Reg. No. 39,529 Sean M. Couglin, Reg. No. 48,593 Attorneys for Applicants c/o MINTZ, LEVIN Address all written correspondence to

Customer no.: 30623 Tel: (202) 585-3577 Fax: (617) 542-2241

Date: March 30, 2009

4576050v.1